Trial Profile
Efficacy of Alemtuzumab on disease control in patients with relapse remitting multiple sclerosis who have stopped natalizumab
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 03 Jul 2017 New trial record
- 01 Jun 2017 Preliminary results (n=16) published in the Neurology and Therapy.